CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop novel therapeutic nanobodies to combat infections caused by Staphylococcus aureus and Pseudomonas aeruginosa in cystic fibrosis patients. The goal is to improve treatment outcomes and enhance the quality of life for individuals affected by this genetic disorder.
Cystic fibrosis (CF) is a genetic disorder, impacting various organs due to CFTR gene mutations.
Lungs are severely affected by secretions, harboring bacteria, causing recurrent, chronic, and often fatal infections in 90% of CF patients.
Globally, around 105,000 people across 94 countries suffer from CF, with an improved median survival age of 30 to 40 years, yet poor quality of life persists due to daily treatment needs.
Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) are the primary…
CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P.
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
